| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| von Willebrand Factor | 55 | 2024 | 205 | 7.580 |
Why?
|
| Blood Platelets | 30 | 2023 | 334 | 2.640 |
Why?
|
| Thrombosis | 13 | 2022 | 543 | 2.470 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 27 | 2022 | 43 | 2.220 |
Why?
|
| Vimentin | 5 | 2022 | 69 | 1.980 |
Why?
|
| Platelet Adhesiveness | 14 | 2019 | 40 | 1.900 |
Why?
|
| Fibrin | 5 | 2024 | 64 | 1.510 |
Why?
|
| Endotoxemia | 3 | 2024 | 55 | 1.300 |
Why?
|
| P-Selectin | 3 | 2020 | 74 | 1.240 |
Why?
|
| Membrane Glycoproteins | 8 | 2020 | 426 | 1.230 |
Why?
|
| Recombinant Proteins | 24 | 2021 | 1419 | 1.190 |
Why?
|
| Cyclonic Storms | 2 | 2022 | 80 | 1.160 |
Why?
|
| Collagen | 10 | 2022 | 311 | 1.080 |
Why?
|
| ADAMTS13 Protein | 15 | 2024 | 67 | 1.020 |
Why?
|
| Platelet Activation | 9 | 2021 | 71 | 0.960 |
Why?
|
| Disseminated Intravascular Coagulation | 4 | 2021 | 67 | 0.910 |
Why?
|
| Endothelium, Vascular | 7 | 2021 | 499 | 0.910 |
Why?
|
| Cell Adhesion | 8 | 2020 | 340 | 0.860 |
Why?
|
| Platelet Aggregation | 11 | 2016 | 115 | 0.860 |
Why?
|
| Protein Binding | 30 | 2020 | 1833 | 0.860 |
Why?
|
| Hemostatics | 1 | 2022 | 61 | 0.760 |
Why?
|
| Leukocytes | 2 | 2020 | 216 | 0.740 |
Why?
|
| Thromboembolism | 2 | 2022 | 92 | 0.720 |
Why?
|
| von Willebrand Diseases | 6 | 2022 | 55 | 0.720 |
Why?
|
| Protein Structure, Tertiary | 21 | 2015 | 778 | 0.710 |
Why?
|
| Peptide Fragments | 5 | 2021 | 811 | 0.660 |
Why?
|
| Genome-Wide Association Study | 12 | 2025 | 1840 | 0.590 |
Why?
|
| Binding Sites | 15 | 2024 | 1360 | 0.590 |
Why?
|
| Polymorphism, Single Nucleotide | 15 | 2025 | 2857 | 0.590 |
Why?
|
| Diabetes Mellitus, Type 2 | 8 | 2024 | 1408 | 0.560 |
Why?
|
| Apolipoprotein A-V | 1 | 2017 | 23 | 0.530 |
Why?
|
| Sepsis | 1 | 2022 | 521 | 0.530 |
Why?
|
| Hemoglobins | 2 | 2015 | 322 | 0.530 |
Why?
|
| Tornadoes | 1 | 2017 | 3 | 0.530 |
Why?
|
| Emergency Shelter | 1 | 2017 | 9 | 0.530 |
Why?
|
| Floods | 1 | 2017 | 18 | 0.520 |
Why?
|
| Metalloendopeptidases | 4 | 2004 | 103 | 0.520 |
Why?
|
| Disaster Planning | 1 | 2017 | 64 | 0.510 |
Why?
|
| Critical Illness | 6 | 2022 | 630 | 0.490 |
Why?
|
| Triglycerides | 3 | 2017 | 614 | 0.480 |
Why?
|
| Safety Management | 1 | 2017 | 121 | 0.480 |
Why?
|
| Disasters | 1 | 2017 | 106 | 0.480 |
Why?
|
| Neutrophils | 1 | 2018 | 369 | 0.470 |
Why?
|
| ADAM Proteins | 10 | 2015 | 87 | 0.460 |
Why?
|
| Humans | 85 | 2025 | 133202 | 0.450 |
Why?
|
| Shear Strength | 1 | 2014 | 17 | 0.440 |
Why?
|
| Platelet Membrane Glycoproteins | 9 | 2013 | 30 | 0.430 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 4 | 2021 | 108 | 0.430 |
Why?
|
| Quantitative Trait, Heritable | 3 | 2021 | 111 | 0.430 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2025 | 3361 | 0.390 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 623 | 0.380 |
Why?
|
| Carrier Proteins | 2 | 2017 | 1071 | 0.380 |
Why?
|
| Inflammation | 6 | 2024 | 1546 | 0.370 |
Why?
|
| Thrombelastography | 3 | 2021 | 60 | 0.370 |
Why?
|
| Hemodynamics | 1 | 2015 | 857 | 0.350 |
Why?
|
| Stress, Physiological | 1 | 2012 | 265 | 0.320 |
Why?
|
| Integrins | 2 | 2000 | 100 | 0.310 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 5 | 2016 | 65 | 0.310 |
Why?
|
| Fibrinogen | 4 | 2022 | 163 | 0.310 |
Why?
|
| Protein Domains | 5 | 2021 | 260 | 0.300 |
Why?
|
| Stress, Mechanical | 7 | 2018 | 176 | 0.300 |
Why?
|
| Multifactorial Inheritance | 3 | 2025 | 168 | 0.300 |
Why?
|
| Kinetics | 10 | 2019 | 1312 | 0.290 |
Why?
|
| Mice, Inbred C57BL | 6 | 2024 | 4818 | 0.290 |
Why?
|
| Animals | 25 | 2024 | 35916 | 0.290 |
Why?
|
| Protein Conformation | 8 | 2021 | 858 | 0.290 |
Why?
|
| Fibrinolysis | 3 | 2022 | 44 | 0.270 |
Why?
|
| Disease Models, Animal | 5 | 2024 | 4725 | 0.270 |
Why?
|
| Protein Structure, Secondary | 4 | 2019 | 248 | 0.260 |
Why?
|
| Brain Injuries, Traumatic | 2 | 2021 | 301 | 0.260 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2019 | 158 | 0.260 |
Why?
|
| Lipid Metabolism | 3 | 2017 | 387 | 0.250 |
Why?
|
| Integrin alpha2beta1 | 2 | 2005 | 9 | 0.240 |
Why?
|
| Mice | 12 | 2024 | 18888 | 0.240 |
Why?
|
| Ristocetin | 7 | 2012 | 8 | 0.240 |
Why?
|
| Alleles | 3 | 2021 | 1693 | 0.220 |
Why?
|
| Mexico | 7 | 2020 | 185 | 0.220 |
Why?
|
| von Willebrand Disease, Type 3 | 1 | 2024 | 6 | 0.220 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 383 | 0.220 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 394 | 0.220 |
Why?
|
| In Vitro Techniques | 7 | 2019 | 915 | 0.220 |
Why?
|
| Hemostasis | 2 | 2023 | 72 | 0.210 |
Why?
|
| Multiprotein Complexes | 3 | 2016 | 218 | 0.210 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2024 | 139 | 0.210 |
Why?
|
| Phenotype | 6 | 2025 | 4571 | 0.210 |
Why?
|
| Quantitative Trait Loci | 2 | 2016 | 314 | 0.210 |
Why?
|
| Models, Molecular | 8 | 2009 | 1128 | 0.200 |
Why?
|
| Citrulline | 1 | 2024 | 114 | 0.200 |
Why?
|
| Histones | 3 | 2019 | 572 | 0.200 |
Why?
|
| Extracellular Space | 1 | 2022 | 86 | 0.200 |
Why?
|
| Polyethylene Glycols | 1 | 2024 | 253 | 0.200 |
Why?
|
| Aspartic Acid | 1 | 2003 | 84 | 0.200 |
Why?
|
| Protein Folding | 4 | 2019 | 222 | 0.200 |
Why?
|
| Obesity, Morbid | 1 | 2025 | 214 | 0.200 |
Why?
|
| Linkage Disequilibrium | 3 | 2019 | 317 | 0.190 |
Why?
|
| United States Virgin Islands | 1 | 2022 | 2 | 0.190 |
Why?
|
| Male | 20 | 2025 | 65411 | 0.190 |
Why?
|
| Puerto Rico | 1 | 2022 | 52 | 0.190 |
Why?
|
| Federal Government | 1 | 2022 | 17 | 0.190 |
Why?
|
| Glycine | 1 | 2003 | 172 | 0.190 |
Why?
|
| Protein Structure, Quaternary | 3 | 2013 | 102 | 0.190 |
Why?
|
| Public Health | 2 | 2022 | 284 | 0.180 |
Why?
|
| Genetic Association Studies | 4 | 2021 | 859 | 0.180 |
Why?
|
| Body Fat Distribution | 1 | 2021 | 32 | 0.180 |
Why?
|
| Mice, Inbred BALB C | 1 | 2024 | 1072 | 0.180 |
Why?
|
| Female | 20 | 2025 | 71456 | 0.180 |
Why?
|
| Mutagenesis, Site-Directed | 5 | 2019 | 319 | 0.180 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2021 | 28 | 0.170 |
Why?
|
| Candida albicans | 1 | 2021 | 89 | 0.170 |
Why?
|
| Interferometry | 1 | 2020 | 25 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 7 | 2011 | 1053 | 0.170 |
Why?
|
| Endothelium | 1 | 2020 | 70 | 0.170 |
Why?
|
| Ferritins | 1 | 2021 | 109 | 0.170 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 211 | 0.160 |
Why?
|
| Candidiasis | 1 | 2021 | 138 | 0.160 |
Why?
|
| Guanine Nucleotide Dissociation Inhibitors | 1 | 2020 | 11 | 0.160 |
Why?
|
| Healthy Volunteers | 1 | 2020 | 152 | 0.160 |
Why?
|
| Adiposity | 1 | 2021 | 207 | 0.160 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2015 | 57 | 0.160 |
Why?
|
| Molecular Docking Simulation | 1 | 2020 | 136 | 0.160 |
Why?
|
| Amino Acid Substitution | 5 | 2019 | 412 | 0.160 |
Why?
|
| von Willebrand Disease, Type 2 | 1 | 2019 | 4 | 0.160 |
Why?
|
| Thrombophilia | 1 | 2020 | 42 | 0.160 |
Why?
|
| Proteostasis Deficiencies | 1 | 2019 | 7 | 0.160 |
Why?
|
| Endothelial Cells | 5 | 2024 | 536 | 0.160 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 294 | 0.160 |
Why?
|
| Casein Kinase I | 1 | 2019 | 12 | 0.160 |
Why?
|
| Cells, Cultured | 9 | 2017 | 3124 | 0.150 |
Why?
|
| Adult | 14 | 2025 | 31742 | 0.150 |
Why?
|
| Middle Aged | 13 | 2025 | 29020 | 0.150 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 267 | 0.150 |
Why?
|
| Graft vs Host Disease | 1 | 2024 | 621 | 0.150 |
Why?
|
| Hypersensitivity | 1 | 2021 | 195 | 0.150 |
Why?
|
| Lipopolysaccharides | 2 | 2024 | 308 | 0.150 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2020 | 147 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2014 | 1704 | 0.150 |
Why?
|
| Mexican Americans | 2 | 2017 | 169 | 0.150 |
Why?
|
| Extracellular Matrix | 1 | 1999 | 241 | 0.150 |
Why?
|
| Gene Frequency | 2 | 2017 | 750 | 0.150 |
Why?
|
| Publishing | 1 | 2020 | 116 | 0.150 |
Why?
|
| Kidney Calculi | 1 | 2019 | 48 | 0.150 |
Why?
|
| Pandemics | 3 | 2022 | 1194 | 0.140 |
Why?
|
| Surface Plasmon Resonance | 4 | 2006 | 52 | 0.140 |
Why?
|
| Hemolytic-Uremic Syndrome | 2 | 2015 | 36 | 0.140 |
Why?
|
| Receptors, Collagen | 3 | 2004 | 7 | 0.140 |
Why?
|
| Mutation | 11 | 2021 | 6314 | 0.140 |
Why?
|
| Crotalid Venoms | 4 | 2011 | 9 | 0.140 |
Why?
|
| Forecasting | 1 | 2019 | 374 | 0.140 |
Why?
|
| Munc18 Proteins | 1 | 2017 | 20 | 0.130 |
Why?
|
| Biomechanical Phenomena | 3 | 2019 | 262 | 0.130 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 197 | 0.130 |
Why?
|
| Calcineurin | 1 | 2017 | 75 | 0.130 |
Why?
|
| Body Mass Index | 5 | 2025 | 1714 | 0.130 |
Why?
|
| Metabolome | 1 | 2019 | 321 | 0.130 |
Why?
|
| Protein Phosphatase 2C | 1 | 2016 | 60 | 0.120 |
Why?
|
| HEK293 Cells | 4 | 2019 | 816 | 0.120 |
Why?
|
| Integrin alpha2 | 1 | 2015 | 10 | 0.120 |
Why?
|
| Membrane Transport Proteins | 1 | 2017 | 183 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 541 | 0.120 |
Why?
|
| Microscopy, Atomic Force | 3 | 2009 | 20 | 0.120 |
Why?
|
| Muscle, Skeletal | 2 | 2020 | 1038 | 0.120 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 1765 | 0.120 |
Why?
|
| Collagen Type I | 2 | 2006 | 124 | 0.120 |
Why?
|
| Epistasis, Genetic | 1 | 2015 | 103 | 0.120 |
Why?
|
| Haplotypes | 1 | 2017 | 544 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2013 | 841 | 0.120 |
Why?
|
| Thermodynamics | 3 | 2010 | 146 | 0.120 |
Why?
|
| Case-Control Studies | 5 | 2021 | 3433 | 0.120 |
Why?
|
| Hemolysis | 1 | 2015 | 114 | 0.120 |
Why?
|
| Cloning, Molecular | 4 | 2003 | 909 | 0.120 |
Why?
|
| Cholesterol, LDL | 2 | 2017 | 600 | 0.110 |
Why?
|
| Apolipoprotein E4 | 1 | 2015 | 48 | 0.110 |
Why?
|
| Thrombin | 2 | 2017 | 62 | 0.110 |
Why?
|
| Genotype | 5 | 2021 | 2717 | 0.110 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 287 | 0.110 |
Why?
|
| Receptors, LDL | 1 | 2015 | 103 | 0.110 |
Why?
|
| Bleeding Time | 1 | 2014 | 8 | 0.110 |
Why?
|
| Actins | 1 | 2016 | 341 | 0.110 |
Why?
|
| Flow Cytometry | 3 | 2014 | 813 | 0.110 |
Why?
|
| Cricetinae | 7 | 2009 | 394 | 0.110 |
Why?
|
| Chromatography, Gel | 2 | 2010 | 96 | 0.110 |
Why?
|
| Multiple Organ Failure | 1 | 2015 | 144 | 0.110 |
Why?
|
| Shiga Toxin 1 | 1 | 2013 | 1 | 0.110 |
Why?
|
| Antibodies | 1 | 2015 | 372 | 0.110 |
Why?
|
| Amino Acid Sequence | 8 | 2019 | 2763 | 0.110 |
Why?
|
| Complement Factor H | 1 | 2013 | 24 | 0.100 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 252 | 0.100 |
Why?
|
| Point Mutation | 2 | 2006 | 353 | 0.100 |
Why?
|
| Cytoskeleton | 1 | 2014 | 172 | 0.100 |
Why?
|
| Lipoproteins, LDL | 1 | 2013 | 137 | 0.100 |
Why?
|
| Serum Albumin | 1 | 2013 | 115 | 0.100 |
Why?
|
| CHO Cells | 6 | 2009 | 165 | 0.100 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3748 | 0.100 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 625 | 0.100 |
Why?
|
| Catalytic Domain | 2 | 2009 | 178 | 0.090 |
Why?
|
| Genetic Loci | 3 | 2019 | 362 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2017 | 1037 | 0.090 |
Why?
|
| Edetic Acid | 2 | 2003 | 25 | 0.090 |
Why?
|
| Molecular Sequence Data | 8 | 2013 | 3937 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2025 | 2745 | 0.090 |
Why?
|
| Stroke | 2 | 2018 | 1078 | 0.090 |
Why?
|
| Algorithms | 2 | 2017 | 1728 | 0.090 |
Why?
|
| Kidney | 1 | 2019 | 1346 | 0.090 |
Why?
|
| Obesity | 2 | 2021 | 2419 | 0.090 |
Why?
|
| Lipid Bilayers | 1 | 2011 | 49 | 0.090 |
Why?
|
| DNA Primers | 2 | 2007 | 652 | 0.090 |
Why?
|
| Base Sequence | 3 | 2007 | 3147 | 0.090 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 806 | 0.090 |
Why?
|
| Hemorheology | 2 | 2008 | 26 | 0.090 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2005 | 289 | 0.080 |
Why?
|
| Serum Albumin, Bovine | 1 | 2010 | 56 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 803 | 0.080 |
Why?
|
| Hypertension | 1 | 2019 | 1348 | 0.080 |
Why?
|
| Signal Transduction | 4 | 2016 | 4848 | 0.080 |
Why?
|
| Protein Phosphatase 1 | 1 | 2009 | 55 | 0.080 |
Why?
|
| Hemoglobin A | 1 | 2009 | 22 | 0.080 |
Why?
|
| Membrane Proteins | 2 | 2009 | 1605 | 0.080 |
Why?
|
| Cattle | 1 | 2010 | 584 | 0.080 |
Why?
|
| Thrombolytic Therapy | 2 | 2021 | 214 | 0.080 |
Why?
|
| Heart-Assist Devices | 1 | 2017 | 1099 | 0.070 |
Why?
|
| Risk Factors | 4 | 2025 | 10935 | 0.070 |
Why?
|
| Apoptosis | 1 | 2015 | 1928 | 0.070 |
Why?
|
| Acute Kidney Injury | 1 | 2015 | 676 | 0.070 |
Why?
|
| Substrate Specificity | 2 | 2009 | 309 | 0.070 |
Why?
|
| Mass Spectrometry | 2 | 2019 | 366 | 0.070 |
Why?
|
| Magnesium Sulfate | 1 | 2008 | 51 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 3 | 2012 | 2585 | 0.070 |
Why?
|
| Atherosclerosis | 1 | 2015 | 996 | 0.060 |
Why?
|
| Fibrinolytic Agents | 1 | 2008 | 208 | 0.060 |
Why?
|
| Collagen Type III | 1 | 2006 | 26 | 0.060 |
Why?
|
| Transfection | 4 | 2017 | 1083 | 0.060 |
Why?
|
| Anticoagulants | 2 | 2021 | 627 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2013 | 1068 | 0.060 |
Why?
|
| Escherichia coli | 3 | 1999 | 1034 | 0.060 |
Why?
|
| Mutagenesis | 2 | 2000 | 354 | 0.060 |
Why?
|
| Microspheres | 2 | 2008 | 74 | 0.060 |
Why?
|
| Mutation, Missense | 2 | 2013 | 940 | 0.060 |
Why?
|
| Anemia, Sickle Cell | 1 | 2009 | 346 | 0.060 |
Why?
|
| COS Cells | 2 | 2003 | 277 | 0.060 |
Why?
|
| Spectrum Analysis | 1 | 2005 | 69 | 0.060 |
Why?
|
| Antibody Affinity | 1 | 2004 | 41 | 0.060 |
Why?
|
| Latin America | 1 | 2025 | 99 | 0.060 |
Why?
|
| United States | 2 | 2017 | 11658 | 0.060 |
Why?
|
| Fibrillar Collagens | 1 | 2004 | 15 | 0.050 |
Why?
|
| Hydrolases | 1 | 2024 | 61 | 0.050 |
Why?
|
| Polystyrenes | 2 | 2003 | 12 | 0.050 |
Why?
|
| Transcription Factor AP-1 | 1 | 2004 | 112 | 0.050 |
Why?
|
| Optics and Photonics | 1 | 2005 | 123 | 0.050 |
Why?
|
| Umbilical Veins | 2 | 2003 | 73 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2019 | 1663 | 0.050 |
Why?
|
| Receptor Aggregation | 1 | 2003 | 5 | 0.050 |
Why?
|
| Sulfoglycosphingolipids | 1 | 2003 | 8 | 0.050 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 2 | 2016 | 63 | 0.050 |
Why?
|
| Immunoassay | 1 | 2003 | 138 | 0.050 |
Why?
|
| Aged | 5 | 2020 | 21480 | 0.050 |
Why?
|
| Puberty | 1 | 2024 | 104 | 0.050 |
Why?
|
| Hemagglutinins | 1 | 2003 | 25 | 0.050 |
Why?
|
| Blood Pressure | 2 | 2019 | 1379 | 0.050 |
Why?
|
| Reference Values | 1 | 2004 | 724 | 0.050 |
Why?
|
| Swine | 2 | 2024 | 1199 | 0.050 |
Why?
|
| Crystallography, X-Ray | 2 | 2002 | 389 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2003 | 105 | 0.050 |
Why?
|
| Body Height | 1 | 2024 | 228 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2024 | 652 | 0.050 |
Why?
|
| Time Factors | 4 | 2008 | 6526 | 0.050 |
Why?
|
| Arginine | 1 | 2024 | 345 | 0.050 |
Why?
|
| Capillary Leak Syndrome | 1 | 2021 | 3 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2024 | 618 | 0.040 |
Why?
|
| Acute-Phase Reaction | 1 | 2021 | 14 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 1 | 2021 | 71 | 0.040 |
Why?
|
| Th2 Cells | 1 | 2021 | 189 | 0.040 |
Why?
|
| Th17 Cells | 1 | 2021 | 101 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2003 | 461 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 2021 | 102 | 0.040 |
Why?
|
| Coronavirus | 1 | 2020 | 27 | 0.040 |
Why?
|
| Extracellular Vesicles | 1 | 2021 | 59 | 0.040 |
Why?
|
| Cations, Divalent | 1 | 1999 | 21 | 0.040 |
Why?
|
| Binding, Competitive | 1 | 1999 | 189 | 0.040 |
Why?
|
| Molecular Conformation | 2 | 2011 | 111 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 1504 | 0.040 |
Why?
|
| Disulfides | 2 | 2003 | 82 | 0.040 |
Why?
|
| Cerebral Hemorrhage | 1 | 2021 | 158 | 0.040 |
Why?
|
| Protein Stability | 2 | 2010 | 175 | 0.040 |
Why?
|
| Cations | 1 | 2019 | 39 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 569 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 687 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2019 | 152 | 0.040 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 149 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 1 | 2000 | 239 | 0.040 |
Why?
|
| Proteins | 1 | 2004 | 1089 | 0.040 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2018 | 35 | 0.040 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 162 | 0.040 |
Why?
|
| Histone Code | 1 | 2019 | 53 | 0.040 |
Why?
|
| Protein Denaturation | 2 | 2009 | 52 | 0.040 |
Why?
|
| Cytokines | 1 | 2024 | 1374 | 0.040 |
Why?
|
| Receptors, Odorant | 1 | 2017 | 40 | 0.030 |
Why?
|
| Cell Line | 3 | 2010 | 2830 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2021 | 798 | 0.030 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2017 | 43 | 0.030 |
Why?
|
| Adolescent | 3 | 2024 | 20594 | 0.030 |
Why?
|
| Cerebrovascular Circulation | 1 | 2021 | 474 | 0.030 |
Why?
|
| Age of Onset | 1 | 2019 | 626 | 0.030 |
Why?
|
| Urea | 2 | 2009 | 237 | 0.030 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2017 | 120 | 0.030 |
Why?
|
| Histamine | 1 | 2017 | 49 | 0.030 |
Why?
|
| Talin | 1 | 2016 | 11 | 0.030 |
Why?
|
| Models, Biological | 3 | 2008 | 1522 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2019 | 382 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 304 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2017 | 150 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2020 | 535 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2019 | 1118 | 0.030 |
Why?
|
| Peptides | 2 | 2016 | 854 | 0.030 |
Why?
|
| Gene Duplication | 1 | 2017 | 372 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 429 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2017 | 393 | 0.030 |
Why?
|
| Shiga Toxins | 1 | 2015 | 2 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2024 | 1191 | 0.030 |
Why?
|
| Blood Coagulation | 1 | 2016 | 134 | 0.030 |
Why?
|
| Complement Inactivating Agents | 1 | 2015 | 12 | 0.030 |
Why?
|
| Waist-Hip Ratio | 1 | 2015 | 59 | 0.030 |
Why?
|
| Family | 1 | 2019 | 596 | 0.030 |
Why?
|
| Thromboplastin | 1 | 2015 | 20 | 0.030 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2015 | 25 | 0.030 |
Why?
|
| Complement System Proteins | 1 | 2015 | 59 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2015 | 110 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2025 | 3714 | 0.030 |
Why?
|
| Pedigree | 1 | 2019 | 1731 | 0.030 |
Why?
|
| Genetics, Population | 1 | 2016 | 190 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2016 | 439 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2017 | 696 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2016 | 299 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2017 | 806 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2014 | 156 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2015 | 310 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2017 | 516 | 0.030 |
Why?
|
| Enterohemorrhagic Escherichia coli | 1 | 2013 | 8 | 0.030 |
Why?
|
| Scavenger Receptors, Class E | 1 | 2013 | 9 | 0.030 |
Why?
|
| Electrochemistry | 1 | 2013 | 25 | 0.030 |
Why?
|
| Protein Kinase C-alpha | 1 | 2013 | 20 | 0.030 |
Why?
|
| Glycosylation | 1 | 1993 | 129 | 0.030 |
Why?
|
| Platelet Function Tests | 1 | 2013 | 41 | 0.030 |
Why?
|
| Cyclic AMP | 1 | 2013 | 240 | 0.020 |
Why?
|
| Linear Models | 1 | 2014 | 718 | 0.020 |
Why?
|
| Perfusion | 2 | 2004 | 209 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 1018 | 0.020 |
Why?
|
| Heterozygote | 1 | 2015 | 729 | 0.020 |
Why?
|
| Lipids | 1 | 2016 | 562 | 0.020 |
Why?
|
| Macaca fascicularis | 2 | 2005 | 88 | 0.020 |
Why?
|
| Transcriptome | 1 | 2019 | 1134 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 897 | 0.020 |
Why?
|
| Precipitin Tests | 1 | 1992 | 155 | 0.020 |
Why?
|
| Heparin | 1 | 1993 | 229 | 0.020 |
Why?
|
| Adenosine Diphosphate | 1 | 1992 | 55 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 302 | 0.020 |
Why?
|
| Nanotechnology | 1 | 2011 | 50 | 0.020 |
Why?
|
| Escherichia coli Infections | 1 | 2013 | 195 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 1262 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2014 | 510 | 0.020 |
Why?
|
| Blood Viscosity | 1 | 2011 | 13 | 0.020 |
Why?
|
| Phospholipids | 1 | 2011 | 107 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 1111 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2013 | 303 | 0.020 |
Why?
|
| Child | 2 | 2024 | 25889 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 558 | 0.020 |
Why?
|
| Genome, Human | 1 | 2017 | 1336 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 2632 | 0.020 |
Why?
|
| Solutions | 1 | 2010 | 62 | 0.020 |
Why?
|
| Receptors, Thrombin | 1 | 2009 | 14 | 0.020 |
Why?
|
| Phosphoserine | 1 | 2009 | 41 | 0.020 |
Why?
|
| Secretory Vesicles | 1 | 2009 | 21 | 0.020 |
Why?
|
| Cricetulus | 1 | 2009 | 97 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2009 | 65 | 0.020 |
Why?
|
| Calorimetry, Differential Scanning | 1 | 2009 | 8 | 0.020 |
Why?
|
| Cell Membrane | 1 | 1992 | 472 | 0.020 |
Why?
|
| Epitopes | 2 | 2004 | 442 | 0.020 |
Why?
|
| Enzyme Repression | 1 | 2009 | 4 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2009 | 88 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2009 | 211 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2009 | 227 | 0.020 |
Why?
|
| Hydrolysis | 1 | 2009 | 161 | 0.020 |
Why?
|
| Antibodies, Blocking | 1 | 2009 | 63 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 7164 | 0.020 |
Why?
|
| Temperature | 1 | 2009 | 323 | 0.020 |
Why?
|
| Cell Shape | 1 | 2008 | 70 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 5175 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2024 | 14906 | 0.020 |
Why?
|
| Magnesium | 1 | 2008 | 119 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2009 | 510 | 0.020 |
Why?
|
| Circular Dichroism | 1 | 2006 | 83 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2008 | 292 | 0.020 |
Why?
|
| DNA | 1 | 1992 | 1671 | 0.020 |
Why?
|
| Texas | 1 | 2014 | 3658 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2006 | 455 | 0.020 |
Why?
|
| Biophysical Phenomena | 1 | 2005 | 40 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2013 | 3978 | 0.010 |
Why?
|
| Biophysics | 1 | 2005 | 50 | 0.010 |
Why?
|
| Valine | 1 | 2004 | 113 | 0.010 |
Why?
|
| Amino Acids | 1 | 2006 | 683 | 0.010 |
Why?
|
| Adhesiveness | 1 | 2003 | 14 | 0.010 |
Why?
|
| Leucine | 1 | 2004 | 311 | 0.010 |
Why?
|
| Receptors, IgG | 1 | 2002 | 63 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 767 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2002 | 186 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2003 | 617 | 0.010 |
Why?
|
| Cholesterol | 1 | 2002 | 565 | 0.010 |
Why?
|
| Papio | 1 | 1997 | 60 | 0.010 |
Why?
|
| Oligopeptides | 1 | 1997 | 120 | 0.010 |
Why?
|
| Calcium | 1 | 1997 | 1085 | 0.010 |
Why?
|